Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies

被引:26
作者
Burky, John E. [1 ]
Wesson, Mark C. [1 ]
Young, Amy [1 ]
Farnsworth, Sharyn [1 ]
Dionne, Ben [1 ]
Zhu, Ying [1 ]
Hartman, Taymar E. [1 ]
Qu, Limin [1 ]
Zhou, Weichang [1 ]
Saner, Paul W. [1 ]
机构
[1] PDL BioPharma Inc, Proc Sci & Engn, Fremont, CA 94555 USA
关键词
NS0 host cell line; fed-batch culture process platform; humanized antibodies; protein-free; lactate consumption;
D O I
10.1002/bit.21060
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Presented is a novel antibody production platform based on the fed-batch culture of recombinant NS0-derived cell lines. A standardized fed-batch culture process was developed for five non-GS NS0 cell lines using enriched and optimized protein-free, cholesterol-free, and chemically defined basal and feed media. The process performed reproducibly and scaled faithfully from the 2-L to the 100-L bioreactor scale achieving a volumetric productivity of > 120 mg/L per day. Fed-batch cultures for all five cell lines exhibited significant lactate consumption when the cells entered the stationary or death phase. Peak and final lactate concentrations were low relative to a previously developed fed-batch process (FBP). Such low lactate production and high lactate consumption rates were unanticipated considering the fed-batch culture basal medium has an unconventionally high initial glucose concentration of 15 g/L, and an overall glucose consumption in excess of 17 g/L. The potential of this process platform was further demonstrated through additional media optimization, which has resulted in a final antibody concentration of 2.64 +/- 0.19 g/L and volumetric productivity of > 200 mg/L per day in a 13-day FBP for one of the five cell production lines. Use of this standardized protein-free, cholesterol-free NS0 FBP platform enables consistency in development time and cost effectiveness for manufacturing of therapeutic antibodies.
引用
收藏
页码:281 / 293
页数:13
相关论文
共 42 条
  • [1] HIGH-LEVEL EXPRESSION OF A RECOMBINANT ANTIBODY FROM MYELOMA CELLS USING A GLUTAMINE-SYNTHETASE GENE AS AN AMPLIFIABLE SELECTABLE MARKER
    BEBBINGTON, CR
    RENNER, G
    THOMSON, S
    KING, D
    ABRAMS, D
    YARRANTON, GT
    [J]. BIO-TECHNOLOGY, 1992, 10 (02): : 169 - 175
  • [2] BIBILA T, 1994, ANN NY ACAD SCI, V745, P277
  • [3] IN PURSUIT OF THE OPTIMAL FED-BATCH PROCESS FOR MONOCLONAL-ANTIBODY PRODUCTION
    BIBILA, TA
    ROBINSON, DK
    [J]. BIOTECHNOLOGY PROGRESS, 1995, 11 (01) : 1 - 13
  • [4] SELECTING AND DESIGNING CELL-LINES FOR IMPROVED PHYSIOLOGICAL-CHARACTERISTICS
    BIRCH, JR
    BORASTON, RC
    METCALFE, H
    BROWN, ME
    BEBBINGTON, CR
    FIELD, RP
    [J]. CYTOTECHNOLOGY, 1994, 15 (1-3) : 11 - 16
  • [5] Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species
    Brand, KA
    Hermfisse, U
    [J]. FASEB JOURNAL, 1997, 11 (05) : 388 - 395
  • [6] Brooks G.A., 1985, CIRC RESP METAB CURR, P208
  • [7] Intra- and extra-cellular lactate shuttles
    Brooks, GA
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2000, 32 (04) : 790 - 799
  • [8] Cain SJ, 1998, BIOTECHNOL BIOENG, V58, P387, DOI 10.1002/(SICI)1097-0290(19980520)58:4<387::AID-BIT6>3.3.CO
  • [9] 2-B
  • [10] Therapeutic antibody expression technology
    Chadd, HE
    Chamow, SM
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2001, 12 (02) : 188 - 194